Please login to the form below
Sangamo
This page shows the latest Sangamo news and features for those working in and with pharma, biotech and healthcare.
Daily Brief: Brexit reshuffle brings new health minister, Celgene thalassemia success, Wellcome read to leap into future
Competition in the therapy area is hotting up, however: Bluebird has recently produced compelling data on its beta-thalassemia gene therapy, with Sangamo also pursuing a similar approach.
Latest news
-
Sarepta soars on positive Duchenne data
Sarepta’s experimental treatment one of a clutch of DMD gene therapies in clinical testing along with candidates from Sangamo, Bamboo/Pfizer, and Solid Biosciences.
-
Freeline raises £88m to accelerate haemophilia gene therapy
Following after is Sangamo with SB-FIX in phase I/II testing. Baxalta (now part of Shire) was an early player in the field with its BAX 335 therapy but has
-
BioMarin ups the ante for pivotal haemophilia gene therapy trial
In the chase are Spark Therapeutics’SPK-8011, Pfizer/Sangamo Biosciences’SB-525 and Shire’s SHP654 - all in phase I/II testing - with uniQure and Sanofi’s Bioverativ unit also
-
Gilead signs $3bn-plus gene-editing deal with Sangamo
Gilead signs $3bn-plus gene-editing deal with Sangamo. Will use the platform for new cell-based cancer therapies. ... Kite will be responsible for all development, manufacturing and commercialisation of products under the collaboration, and will be
-
Third time lucky? Sanofi cuts an $11.6bn deal to buy Bioverativ
Buying Bioverativ does give it a stake in advanced approaches for haematological diseases however, as the biotech has an established collaboration with Sangamo Therapeutics looking at genome-editing approaches to beta
More from news
Approximately 4 fully matching, plus 9 partially matching documents found.
Latest Intelligence
-
Deal Watch table for January 2014
320. Sangamo/Biogen Idec . Collaboration and licence. Development of therapies for haemoglobinopathies using zinc finger genome editing.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest appointments
-
Eric Rhodes becomes CEO of ERS Genomics
Prior to joining Horizon Discovery, Rhodes held a number of senior positions including director of business development at Sigma-Aldrich and vice president of business development and alliance management at Sangamo
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Featured jobs
- Strategic Planner, Healthcare Advertising
-
£47, 000 – £53, 000
- Senior Medical Writer, Healthcare Advertising Agency
-
£45, 000 – £50, 000
-
Healthcare PR Director
-
£100, 000 – £120, 000 benefits
-
Client Services Director - Med Comms
-
Great salary and bebefits
- Account Director, Consumer Healthcare PR, Global PR agency
-
£50, 000 – £58, 000
-
Senior Account Manager
-
Competitive salary commensurate with experience
- Home based, Editorial Team Leader, Medical Communications
-
Excellent package
- Head of Market Access - International - Based Cambridge
-
Excellent Basic, Bonus and Flex Benefits
- Business Unit Head, Medical Communications, London
-
Excellent package
- Home based, Principal Medical Writer, Medical Communications
-
Excellent package
-
Account Manager
-
£40, 000 - £45, 000 benefits
- Account Director, Medical Communications
-
C£50 – 65, 000 benefits and bonus
- Home based, Chief Medical Writer, Medical Communications
-
Excellent package
- Principal Medical Writer / Editorial Director – Medical Communic...
-
£60, 000 - £80, 000
- Home based, Senior Medical Writer, Medical Communications
-
Excellent package
- Account Manager, Medical Communications and Marketing
-
£30, 000 – £40, 000 benefits and bonus
Subscribe to our email news alerts
- Moving annual total (MAT)
- Brexit rebels win vote on European Medicines Agency alignment
- MaxCyte gets green light for solid tumour cell therapy
- Communiqué Awards 2018: Photo Gallery - Communiqué Awards 2016
- NHS England to Vertex: come clean on Orkambi offer
- AstraZeneca joins Merck in Brexit stockpiling effort
- Random42 win Creativity International Award for Scientific Animation
- Merck & Co joins big pharma pricing pledge – but sceptics unconvinced
- Aurora partners with PIPHealth and taps into patient panels
- FDA’s Gottlieb lambasts industry’s biosimilar-blocking tactics
- Allergan’s abicipar matches AMD blockbuster Lucentis in phase III
- OUTiCO growth in multi-channel creates more job openings
PMHub
Hanson Zandi
Hanson Zandi is a Creative and Digital Healthcare Agency. We combine 30 years’ experience with the enthusiasm of a start-up...
Latest intelligence
- Developing advocacy in the pharmaceutical industry.
- The importance of advocacy programmes...
- GDPR and events. What does the pharma industry need to know?
- Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
- Digital trends in B2B sales - how far behind is Pharma?
- The modern approach to B2B sales is data-driven, and enabled by digital tools....
Quick links
Infographics
